Thierry Laugel, PhD

Managing partner, Kurma Life Sciences Partners – Board member
Linkedin

Thierry Laugel is the managing partner of Kurma Life Science Partners. Thierry holds a PhD in pharmacology and an MBA from INSEAD.

After his dissertation, Thierry was a scientific representative for Laboratoires Fournier in Japan for four years at a time when Lipanthyl was released in Japan and research programmes were being rolled out with Grelan, a Takeda Group company.

He subsequently joined Flamel Technologies after its IPO on Nasdaq, as project director for Pharmaceutical R&D. In 1998, he moved to the investment world, firstly at CDC Innovation and then with AGF Private Equity, where he supervised the healthcare investment team.

He subsequently co-founded Kurma Life Sciences in 2008.

Management team

Scientific Advisor

Jean-Philippe Herbeuval, PhD

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors​

Scientific Advisory Board

Jean-Philippe Herbeuval, PhD

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Michel Bouvier, PhD

Michel Bouvier, PhD

Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Martine Smit, PhD

Martine Smit, PhD

Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam

Graeme Milligan, PhD

Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow
Linkedin

About Us

Science

Support & contact

Ermium Therapeutics © 2023 All Rights Reserved

Design by Cédric Adam

close